2. Search Result
Search Result
Results for "

cyclic

" in MCE Product Catalog:

271

Inhibitors & Agonists

3

Screening Libraries

7

Biochemical Assay Reagents

89

Peptides

60

Natural
Products

28

Recombinant Proteins

17

Isotope-Labeled Compounds

4

Antibodies

Cat. No. Product Name Target Research Area
  • HY-P3193A
    Cyclic nona-L-arginine hydrochloride

    		Peptides Others
    Cyclic nona-L-arginine hydrochloride, a nonaarginine peptide used for drug delivery, translocates faster than their linear counterparts.
  • HY-P3193
    Cyclic nona-L-arginine TFA

    		Peptides Others
    Cyclic nona-L-arginine TFA, a nonaarginine peptide used for drug delivery, translocates faster than their linear counterparts.
  • HY-P4102
    Cyclic PSAP peptide

    		Peptides Cancer
    Cyclic PSAP peptide is a cyclic pentapeptide (DWLPK). Cyclic PSAP peptide exhibits agent-like properties and could inhibit metastatic spread and restrain tumor development in general in vivo.
  • HY-P1949
    Cyclic MKEY

    		Peptides Cancer Cardiovascular Disease
    Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice.
  • HY-P1949A
    Cyclic MKEY TFA

    		Peptides Cancer Cardiovascular Disease
    Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice.
  • HY-P4100
    Cyclic SSTR agonist octreotide

    		Somatostatin Receptor Others
    Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic Somatostatin Receptor SSTR agonist.
  • HY-P0084
    Cyclic somatostatin

    SRIF-14; Somatostatin-14

    		 Peptides Neurological Disease Cardiovascular Disease
    Cyclic somatostatin (SRIF-14) is a growth hormone-release inhibiting factor used in the research of severe, acute hemorrhages of gastroduodenal ulcers. Cyclic somatostatin is a neuropeptide co-stored with acetylcholine in the cardiac parasympathetic innervation, exerts influences directly on contraction of ventricular cardiomyocytes. Cyclic somatostatin inhibits the contractile response of isoprenaline with an IC50 value of 13 nM. Cyclic somatostatin can be used for the research of cardiovascular disease.
  • HY-P1789
    CTTHWGFTLC, CYCLIC

    		MMP Cancer Inflammation/Immunology
    CTTHWGFTLC, CYCLIC is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM.
  • HY-P1789A
    CTTHWGFTLC, CYCLIC TFA

    		MMP Cancer Inflammation/Immunology
    CTTHWGFTLC, CYCLIC TFA is a cyclic peptide inhibitor for matrix metalloproteinases MMP-2 and MMP-9. The IC50 value for MMP-9 is ~8 μM.
  • HY-P1206
    CH 275

    		Somatostatin Receptor Neurological Disease
    CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst1) with a Ki of 52 nM. CH 275 acts as a potent and selective sst1 agonist (IC50=30.9 nM) and also displays IC50 values of 345 nM, >1 μM, >10 μM, >10 μM for human sst3, sst4, sst2 and sst5, respectively. CH 275 can be used for the research of alzheimer’s disease.
  • HY-P3557
    Mibenratide

    		Adrenergic Receptor Cardiovascular Disease
    Mibenratide, a small cyclic peptide, is an adrenergic β1 receptor antagonist. Mibenratide can be used for heart failure research.
  • HY-35028
    Boc-Glu-Ofm

    		Amino Acid Derivatives Others
    Boc-Glu-Ofm is a peptide. Boc-Glu-Ofm has been used for the synthesis of ester insulin and cyclic peptide mixtures.
  • HY-P3929
    PKI (14-24)amide

    		PKA Cancer
    PKI (14-24)amide is a potent PKA inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate.
  • HY-P3929A
    PKI (14-24)amide TFA

    		PKA Cancer
    PKI (14-24)amide TFA is a potent PKA inhibitor. PKI (14-24)amide strongly inhibited cyclic AMP-dependent protein kinase activity in the cell homogenate.
  • HY-W036160
    N-Fmoc-O-ethyl-L-homoserine

    		Amino Acid Derivatives Others
    N-Fmoc-O-ethyl-L-homoserine is an homoserine derivative, can be used in cyclic peptide compounds synthesis, as a reducing reagent.
  • HY-P2171
    CCP peptide

    		Peptides Inflammation/Immunology
    CCP peptide is a synthetic cyclic citrullinated peptide (CCP) and used as the substrate for detecting anti-CCP antibodies serologically. CCP peptide functions as a target for autoantibodies with a very high specificity for rheumatoid arthritis (RA).
  • HY-B1811
    Vasopressin

    		Endogenous Metabolite Neurological Disease
    Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors.
  • HY-P2171A
    CCP peptide TFA

    		Peptides Inflammation/Immunology
    CCP peptide TFA is a synthetic cyclic citrullinated peptide (CCP) and used as the substrate for detecting anti-CCP antibodies serologically. CCP peptide TFA functions as a target for autoantibodies with a very high specificity for rheumatoid arthritis (RA).
  • HY-P3777
    β-Bag cell peptide

    		Potassium Channel Neurological Disease
    β-Bag cell peptide is a neuroactive peptide. β-Bag cell peptide elevates cyclic AMP levels in the bag cell neurons. β-Bag cell peptide decreases the amplitudes of the voltage-dependent potassium currents.
  • HY-P4012
    [Asu1,6-Arg8]Vasopressin

    		Vasopressin Receptor Endocrinology
    [Asu1,6-Arg8]Vasopressin is an vasopressin agonist which potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-releasing factor (CRF) in rat anterior pituitary cells in culture.
  • HY-P2698
    1-Alaninechlamydocin

    		HDAC Apoptosis Cancer
    1-Alaninechlamydocin, a cyclic tetrapeptide, is a potent HDAC inhibitor (IC50=6.4 nM). 1-Alaninechlamydocin induces G2/M cell cycle arrest and apoptosis in MIA PaCa-2 cells.
  • HY-P1178
    Cyclotraxin B

    		Trk Receptor Neurological Disease
    Cyclotraxin B, a cyclic peptide, is a highly potent and selective TrkB inhibitor without altering the binding of BDNF. Cyclotraxin B non-competitively inhibits BDNF-induced TrkB activity with an IC50  of  0.30 nM. Cyclotraxin B can crosse the blood-brain-barrier and has analgesic and anxiolytic-like behavioral effects.
  • HY-P1178A
    Cyclotraxin B TFA

    		Trk Receptor Neurological Disease
    Cyclotraxin B TFA, a cyclic peptide, is a highly potent and selective TrkB inhibitor without altering the binding of BDNF. Cyclotraxin B TFA non-competitively inhibits BDNF-induced TrkB activity with an IC50  of  0.30 nM. Cyclotraxin B TFA can crosse the blood-brain-barrier and has analgesic and anxiolytic-like behavioral effects.
  • HY-120822
    Cyclotheonamide A

    		Ser/Thr Protease Cardiovascular Disease
    Cyclotheonamide A is a serine protease inhibitor (cyclic polypeptide), which can be obtained from marine sponges of the genus Theonella. Cyclotheonamide A shows potent inhibitory activity against trypsin (Ki=0.023 µM) and streptokinase (Ki=0.035 µM) and moderate inhibitory activity against human α-thrombin (Ki=0.18 µM). Cyclotheonamide A can be used in study of antithrombotic.
  • HY-P3448
    Certepetide

    CEND-1; iRGD

    		 Integrin Complement System Cancer
    Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
  • HY-125153
    Bursin

    		Peptides Others
    Bursin is a peptide that can be isolated from the bursa of Fabricius of chicken. Bursin induces the phenotypic differentiation of mammalian and avian B precursor cells. Bursin also increases cyclic guanosine monophosphate in cells of the human B-cell line Daudi.
  • HY-P2569
    Malformin A1

    		Apoptosis Cancer
    Malformin A1, a cyclic pentapeptide isolated from Aspergillus niger, possess a range of bioactive properties including antibacterial activity. Malformin A1 shows potent cytotoxic activities on human colorectal cancer cells. Malformin A1 induces apoptosis by activating PARP, caspase 3, -7, and -9.
  • HY-P1045
    187-1, N-WASP inhibitor

    		Arp2/3 Complex Others
    187-1, N-WASP inhibitor, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC50 of 2 μM. 187-1, N-WASP inhibitor prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein.
  • HY-P1045A
    187-1, N-WASP inhibitor TFA

    		Arp2/3 Complex Others
    187-1, N-WASP inhibitor TFA, a 14-aa cyclic peptide, is an allosteric neural Wiskott-Aldrich syndrome protein (N-WASP) inhibitor. 187-1, N-WASP inhibitor TFA potently inhibits actin assembly induced by phosphatidylinositol 4,5-bisphosphate (PIP2) with an IC50 of 2 μM. 187-1, N-WASP inhibitor TFA prevents the activation of Arp2/3 complex by N-WASP by stabilizing the autoinhibited state of the protein.
  • HY-P0027
    Jasplakinolide

    		Arp2/3 Complex Fungal Cancer Infection
    Jasplakinolide is a potent actin polymerization inducer and stabilizes pre-existing actin filaments. Jasplakinolide binds to F-actin competitively with phalloidin with a Kd of 15 nM. Jasplakinolide, a naturally occurring cyclic peptide from the marine sponge, has both fungicidal and anti-cancer activity.
  • HY-149205
    CXJ-2

    		PI3K ERK Inflammation/Immunology
    CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy.
  • HY-P5033
    Cyclo(Gly-His)

    		Peptides Cancer
    Cyclo(Gly-His) is a liposome-encapsulated cyclic dipeptide with antimicrobial and anticancer activity. Cyclo(Gly-His) has cytotoxicity for HeLa and MCF-7 cell with IC50 values of 1.699 mM and 0.358 mM, respectively. Cyclo(Gly-His) can be used for the research of drug delivery systems.
  • HY-P1674
    Murepavadin

    POL7080

    		 Bacterial Antibiotic Infection
    Murepavadin (POL7080), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with both MIC50 and MIC90 values of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance.
  • HY-P1674A
    Murepavadin TFA

    POL7080 TFA

    		 Bacterial Antibiotic Infection
    Murepavadin (POL7080) (TFA), a 14-amino-acid cyclic peptide, is a highly potent, specific antibiotic. Murepavadin exhibits a potent antimicrobial activity for P. aeruginosa with MIC50 and MIC90 values both of 0.12 mg/L. Murepavadin also can target the lipopolysaccharide transport portin D. Murepavadin can be used for the research of bacterial resistance.
  • HY-P1934A
    Cyclo(L-Phe-L-Pro)

    		Fungal IFNAR Reactive Oxygen Species Cancer Inflammation/Immunology Infection
    Cyclo(L-Phe-L-Pro), isolated from Pseudomonas fluorescens and Pseudomonas alcaligenes cell-free culture supernatants is an antifungal cyclic dipeptide. Cyclo(L-Phe-L-Pro) inhibits IFN-β production by interfering with retinoic-acid-inducible gene-I (RIG-I) activation. Cyclo(L-Phe-L-Pro) exhibits free-radical scavenging activity with the IC50 of 24 µM in the DPPH assay.
  • HY-131115
    Cyclo(Tyr-Leu)

    		Peptides Others
    Cyclo(Tyr-Leu) is a cyclic dipeptide.
  • HY-131110
    Cyclo(Ala-Glu)

    		Peptides Others
    Cyclo(Ala-Glu) is a cyclic dipeptide.
  • HY-131111
    Cyclo(Gly-Gln)

    		Peptides Others
    Cyclo(Gly-Gln) is a cyclic dipeptide.
  • HY-N9526
    Lyciumin B

    		Peptides Cardiovascular Disease
    Lyciumin B is a cyclic peptide isolated from Lysium chinense.
  • HY-P1017
    MDL 29913

    		Neurokinin Receptor Neurological Disease Cardiovascular Disease
    MDL 29913, a cyclic pseudopeptide, is a competitive NK2 tachykinin receptor selective antagonist, with a pA2 of 8.66.
  • HY-P1975
    Aureobasidin A

    Basifungin

    		 Fungal Infection Inflammation/Immunology
    Aureobasidin A (Basifungin), a cyclic depsipetide, is an antifungal antibiotic. Aureobasidin A (Basifungin) A is an inhibitor of the inositolphosphorylceramide synthase AUR1.
  • HY-B0686
    Eptifibatide

    		Integrin Cardiovascular Disease
    Eptifibatide is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
  • HY-P3957
    Urotensin II, teleost fish

    		Peptides Others
    Urotensin II, teleost fish is a cyclic peptide. It can be isolated from the caudal neurosecretory system of teleost fish.
  • HY-P1973
    Cyclosporin B

    		Peptides Inflammation/Immunology
    Cyclosporin B is a group of nonpolar cyclic oligopeptides with immunosuppressive activity. Cyclosporin B is used for the prevention of graft rejection in organ transplantation.
  • HY-B0686A
    Eptifibatide monoacetate

    		Integrin Cardiovascular Disease
    Eptifibatide monoacetate is a cyclic heptapeptide, acts as a competitive antagonist for the activated platelet glycoprotein IIb/IIIa receptor, with anti-platelet activity.
  • HY-P4006
    [Pmp1,Tyr(OEt)2] AVP

    		Peptides Others
    [Pmp1,Tyr(OEt)2] AVP is a linear analogue of a cyclic Vasopressin (AVP; HY-B1811) antagonist.
  • HY-13621
    Elisidepsin

    PM02734

    		 Peptides Cancer
    Elisidepsin (PM02734) is cyclic depsipeptide with antineoplastic activity. Elisidepsin inhibits cancer cell proliferation. Elisidepsin can be used in the research of cancers, such as NSCLC.
  • HY-129077
    FR179642

    		Fungal Infection
    FR179642 is a key intermediate in the synthesis of the echinocandin antifungal Micafungin. FR179642 is the cyclic peptide nucleus of the echinocandin-like antifungal lipopeptide FR901379.
  • HY-P4705
    Hymenistatin I

    		Peptides Inflammation/Immunology
    Hymenistatin I is a cyclic octapeptide [c-(-Pro-Pro-Tyr-Val-Pro-Leu-Ile-ile-Ile-)] with immunosuppressive activity in both humoral and cellular immune responses.
  • HY-P2526
    LyP-1

    		Peptides Cancer
    LyP-1 is a cyclic 9‐amino‐acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells.
  • HY-P2526A
    LyP-1 TFA

    		Peptides Cancer
    LyP-1 TFA is a cyclic 9‐amino‐acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells.
  • HY-P4111
    Peptide R

    		CXCR Cancer
    Peptide R, a cyclic peptide, is a specific CXCR4 antagonist. Peptide R shows outstanding capacities to profoundly remodel the tumor stroma. Peptide R has the potential for tumor research.
  • HY-P4811
    Prepro-Atrial Natriuretic Factor (26-55) (human)

    		Peptides Metabolic Disease
    Prepro-Atrial Natriuretic Factor (26-55) (human) is a polypeptide that increases renal cortical and medullary cyclic GMP levels. Prepro-Atrial Natriuretic Factor (26-55) (human) increases renal guanylate cyclase activity.
  • HY-P0122
    iRGD peptide

    c(CRGDKGPDC)

    		 Integrin Cancer
    iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to av integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties.
  • HY-P3156
    Syringomycin E

    		Fungal Infection
    Syringomycin E is an antifungal cyclic lipodepsinonapeptide. Syringomycin E exhibits growth inhibition of Saccharomyces cerevisiae through interaction with the plasma membrane. Syringomycin E causes K + efflux, Ca 2+ influx, and changes in membrane potential, and is related to channel formation.
  • HY-P0303
    Crustacean Cardioactive Peptide

    CCAP

    		 Peptides Neurological Disease Cardiovascular Disease
    Crustacean Cardioactive Peptide (CCAP) is a highly conserved, amidated cyclic nonapeptide, first isolated from the pericardial organs of the shore crab Carcinus maenas, where it has a role in regulating heartbeat; Crustacean Cardioactive Peptide (CCAP) also modulates the neuronal activity in other arthropods.
  • HY-P1179
    Guanylin(human)

    		Guanylate Cyclase Endogenous Metabolite Cancer Endocrinology
    Guanylin(human), a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism.
  • HY-P3958
    BIM-23027

    		Peptides Neurological Disease
    BIM-23027 is a selective agonist of sst2 receptor (EC50=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism.
  • HY-P3899
    [Nle8] Somatostatin (1-28)

    		Somatostatin Receptor Metabolic Disease
    [Nle8] Somatostatin (1-28) is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) increases the amylase release.[Nle8] Somatostatin (1-28) increases the cyclic AMP in pancreatic acini .
  • HY-P1179A
    Guanylin(human) TFA

    		Guanylate Cyclase Endogenous Metabolite Metabolic Disease
    Guanylin(human) TFA, a 15-amino acid peptide, is an endogenous intestinal guanylate cyclase activator. Guanylin(human) TFA is mainly found in gastrointestinal tract which regulates electrolytead water transport in intestinal and renal epithelia through cyclic GMP-dependent mechanism.
  • HY-P3785
    PKI(5-22)amide

    		PKA Neurological Disease
    PKI(5-22)amide is the active inhibitory fragment of the inhibitor of the cyclic AMP-dependent protein kinase (PKA). PKI(5-22)amide inhibits PKA activation, but fails to attenuate homologous desensitization of CRF1 receptors.
  • HY-N6693
    Valinomycin

    NSC 122023

    		 Bacterial Apoptosis Antibiotic Autophagy Infection
    Valinomycin (NSC 122023), a cyclic depsipeptide antibiotic, act as a potassium selective ionophore. Valinomycin (NSC 122023) inhibits lymphocyte proliferation by its effects on the cell membrane, and induces apoptosis in CHO cells. Valinomycin induces activation of PINK1 leading to Parkin Ser65 phosphorylation.
  • HY-P1420
    TAT-cyclo-CLLFVY

    		HIF/HIF Prolyl-Hydroxylase Cancer
    TAT-cyclo-CLLFVY is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM.
  • HY-P4320
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10)

    		Integrin Peptides Cancer
    Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge:cys1-cys10), a decapeptide containing a cyclic RGD active sequence, is an Integrin αIIbβ3 antagonist that inhibits platelet and Adhesion of proMMP-13.
  • HY-P3492
    SARS-CoV-2-IN-34

    		SARS-CoV Infection
    SARS-CoV-2-IN-34 (S-20-1) is a blood brain barrier penetrable pan-coronavirus (CoV) fusion inhibitor with broad-spectrum inhibitory activity. SARS-CoV-2-IN-34 effectively inhibits infection by pseudotyped and authentic SARS-CoV-2, and pseudotyped variants of concern (VOCs). SARS-CoV-2-IN-34 shows high affinity to RBD in S1 and HR1 domain in S2 of SARS-CoV-2 S protein. SARS-CoV-2-IN-34 can be used for the research of infection.
  • HY-P1420A
    TAT-cyclo-CLLFVY TFA

    		HIF/HIF Prolyl-Hydroxylase Cancer
    TAT-cyclo-CLLFVY TFA is a cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. TAT-cyclo-CLLFVY TFA disrupts HIF-1α/HIF-1β protein-protein interaction with an IC50 of 1.3 μM.
  • HY-P1202
    CYN 154806

    		Somatostatin Receptor Endocrinology
    CYN 154806, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC50 values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.
  • HY-106783
    Polymyxin B nonapeptide

    		Bacterial Antibiotic Infection
    Polymyxin B nonapeptide is a cyclic peptide obtained from Polymyxin B by proteolytic removal of its terminal amino acyl residue. Polymyxin B nonapeptide is less toxic, lacks bactericidal activity, and retains its ability to render gram-negative bacteria susceptible to several antibiotics by permeabilizing their outer membranes.
  • HY-P1202A
    CYN 154806 TFA

    		Somatostatin Receptor Endocrinology
    CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC50 values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.
  • HY-P2168
    Demoxytocin

    		Oxytocin Receptor Endocrinology
    Demoxytocin, a heterodetic cyclic peptide, is an analog of oxytocin. Demoxytocin affects the permeability of the cell membrane, increasing the content of calcium ions in smooth muscle cells, increasing its contraction. Demoxytocin also stimulates the contraction of smooth muscles of the uterus. Demoxytocin has the function of oxytocin. Demoxytocin can be used to research stimulation of labor in cases of premature rupture.
  • HY-106783A
    Polymyxin B nonapeptide TFA

    		Bacterial Infection
    Polymyxin B nonapeptide TFA is a cyclic peptide obtained from Polymyxin B by proteolytic removal of its terminal amino acyl residue. Polymyxin B nonapeptide TFA is less toxic, lacks bactericidal activity, and retains its ability to render gram-negative bacteria susceptible to several antibiotics by permeabilizing their outer membranes.
  • HY-P3148
    Astin B

    		Apoptosis Autophagy Reactive Oxygen Species JNK Bcl-2 Family Caspase Metabolic Disease
    Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression.
  • HY-P0178
    LXW7

    		Integrin Inflammation/Immunology
    LXW7, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.
  • HY-P1036
    Compstatin

    		Complement System Others
    Compstatin, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin inhibits only the activation of primates’ complement system. Compstatin exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
  • HY-148195
    NNZ 2591

    		Peptides Neurological Disease
    NNZ 2591 is a synthetic analogue of a small peptide of cyclic glycine proline (cGP). NNZ 2591 shows orally active and cross the blood-brain barrier. NNZ 2591 shows neuroprotective after ischemic brain injury. NNZ 2591 improves motor function in a rat model of Parkinson's disease. NNZ 2591 has the potential for the research of ischemic brain injury and angelman syndrome.
  • HY-P0178A
    LXW7 TFA

    		Integrin Inflammation/Immunology
    LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor. LXW7 has a high binding affinity to αvβ3 integrin with an IC50 of 0.68 μM. LXW7 TFA increases phosphorylation of VEGFR-2 and activation of ERK1/2. Anti-inflammatory effect.
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain.
  • HY-P1036A
    Compstatin TFA

    		Complement System Others
    Compstatin TFA, a 13-residue cyclic peptide, is a potent inhibitor of the complement system C3 with species specificity. Compstatin TFA binds to baboon C3 and is resistant to proteolytic cleavage in baboon blood (similar to humans). Compstatin TFA inhibits only the activation of primates’ complement system. Compstatin TFA exhibits IC50 values of 63 μM and 12 μM for classical and alterative complement pathway, respectively.
  • HY-P2090
    Angiopeptin

    		Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research.
  • HY-P1195A
    PDZ1 Domain inhibitor peptide TFA

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain.
  • HY-P2090A
    Angiopeptin TFA

    		Somatostatin Receptor Adenylate Cyclase Cardiovascular Disease
    Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research.
  • HY-P2300
    Cyclo(Arg-Gly-Asp-D-Phe-Cys)

    Cyclo(RGDfC)

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.
  • HY-P2228
    Chlamydocin

    		HDAC Apoptosis Cancer
    Chlamydocin, a fungal metabolite, is a highly potent HDAC inhibitor, with an IC50 of 1.3 nM. Chlamydocin exhibits potent antiproliferative and anticancer activities. Chlamydocin induces apoptosis by activating caspase-3.
  • HY-P1075
    CALP3

    		Calcium Channel Cancer Neurological Disease
    CALP3, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia.
  • HY-P1075A
    CALP3 TFA

    		Calcium Channel Cancer Neurological Disease
    CALP3 TFA, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia.
  • HY-P2300A
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA

    Cyclo(RGDfC) TFA

    		 Integrin Cancer
    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors.
  • HY-P1821
    Myelin Basic Protein

    MHP4-14

    		 PKC Neurological Disease
    Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (Km=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca 2+/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts.
  • HY-P1320A
    [Nphe1]Nociceptin(1-13)NH2 TFA

    		Opioid Receptor Inflammation/Immunology
    [Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pKi=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA2=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent.
  • HY-P1320
    [Nphe1]Nociceptin(1-13)NH2

    		Opioid Receptor Inflammation/Immunology
    [Nphe1]Nociceptin(1-13)NH2, a novel nociceptin/orphanin FQ (NC) endogenous ligand, is a selective and competitive ociceptin receptor antagonist without any residual agonist activity. [Nphe1]nociceptin(1-13)NH2 binds selectively to recombinant nociceptin receptors (pKi=8.4) and antagonizes the inhibitory effects of nociceptin on cyclic AMP accumulation in CHO cells (pA2=6.0). [Nphe1]Nociceptin(1-13)NH2 has the potential to act as an analgesic agent.